RBC Capital analyst Srini Pajjuri raised the price target on Lam Research (NASDAQ: LRCX) to $290.00 (from $260.00) while maintaining an Outperform rating.

“LRCX reported strong Dec-25Q results driven by healthy WFE environment and share gains.

Management sees ~23% WFE growth in 2026, above our expectations, and believes that the company can continue to outgrow the market.

While NAND spending remains lumpy, LRCX has made solid progress in Foundry and is benefiting from CoWoS/HBM strength.

We expect WFE momentum to sustain into 2027 on the back of GenAI demand and extreme supply tightness in Memory. Tech transitions such as MolyB, Backside Power, and 4F 2 offer additional tailwinds.

We raise estimates, raise PT from $260 to $290, and reiterate Outperform.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Tracking this call

Since this note+39% LRCX $239.58 → $333.89 (Oct 7) · target reached

This call at 6 months✓ Target reached on May 6, 2026, 3 months after the note.

Firm track recordRBC Capital reached 82% of its 39 scored targets within six months (#3 of 31 firms); on Lam Research, 2 of 2. Accuracy ranking →

Earnings reactionOne of 18 notes after Lam Research’s Jan 28 results: 16 of 18 raised targets. See every call →
RBC Capital on Lam Research · target history
Jan 14, 2026 · $260 · Buy Jan 29, 2026 · $290 · Buy · this note Apr 23, 2026 · $310 · Buy
Share
Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.